Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 6/20 | 0.54 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.43 |
| ▸ | DHODH | Q02127 | 1/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | MARS1 | P56192 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CCR6 | P51684 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.38 |
| ▸ | PTGES | O14684 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22004110 | 0.86 | ACLY (0.57) | ACLYF2RL3HSD11B1KMT2APTGES | |
| SCHEMBL22004376 | 0.83 | ACLY (0.52) | ACLYDHODHHSD11B1MARS1CYP3A4 | |
| SCHEMBL22021620 | 0.83 | ACLY (0.50) | ACLYCYP3A4KMT2ASMN1; SMN2 | |
| SCHEMBL7799883 | 0.82 | KMT2A (0.50) | ACLYHSD11B1KMT2AMEN1LMNA | |
| SCHEMBL22004165 | 0.81 | ACLY (0.55) | ACLYF2RL3CYP3A4PTGES | |
| SCHEMBL22022198 | 0.81 | ACLY (0.55) | ACLYF2RL3 | |
| SCHEMBL8942357 | 0.76 | KMT2A (0.66) | ACLYKMT2AMEN1 | |
| SCHEMBL22004314 | 0.75 | ACLY (0.51) | ACLYF2RL3KMT2AKCNH2 | |
| SCHEMBL22004394 | 0.74 | KCNH2 (0.48) | ACLYKMT2AMEN1KCNH2 | |
| SCHEMBL22004328 | 0.73 | ACLY (0.53) | ACLYKMT2AMAPK1PTGES |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200157076-A1 | ACLY INHIBITORS AND USES THEREOF | NIMBUS DISCOVERY, INC. | 2020-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200157076-A1 | ACLY INHIBITORS AND USES THEREOF | ACLY, ATP5ME, ATP5MG | ACLY 1/4885F2RL3 4563/4885DHODH 219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.